- A study of 54 papers found 16 medicinal plants with anti-diabetic molecular evidence
- Four plants had the strongest evidence: Gymnema, white mulberry, red ginseng, and pomegranate
- Nearly all evidence comes from lab studies, not human clinical trials
- The review received no outside funding, with no incentive for drug companies to support plant research
- A fiber-rich diet with polyphenol-dense plants remains the most reliable foundation for blood sugar control
Diabetes now affects roughly 589 million adults worldwide, according to 2024 estimates from the International Diabetes Federation, with more than 80 percent of cases in low- and middle-income countries where standard treatment is often out of reach. Conventional drugs sometimes help, but they come with side effects and costs that many patients cannot absorb — which is why researchers keep returning to the plants people used long before there was a pharmaceutical industry to sell them anything.
A review published June 3 in The Open Biochemistry Journal set out to test that instinct against the evidence. A team whose lead author is Sara Ouari of University Ferhat Abbas Sétif 1 in Algeria, working with colleagues in Algeria and Greece, searched Scopus, ScienceDirect and Google Scholar for studies published between 2000 and 2025. From nearly 1,250 initial records, they kept 54 studies covering 16 medicinal plants with documented molecular evidence of anti-diabetic activity. Notably, the work received no outside funding.
Four plants with the strongest evidence
The 16 species come from wildly different botanical families, yet the review found them converging on the same handful of biological targets. Their active compounds — flavonoids, polyphenols, alkaloids and saponins — interfere with the gut enzymes that break carbohydrates into sugar, strengthen the insulin signals that tell cells to pull glucose out of the blood, and blunt the oxidative damage that wears on the pancreas, liver and kidneys.
Four plants earned the review's top evidence rating. Gymnema sylvestre, called "Gurmar," is among the most thoroughly studied of the group; its gymnemic acids appear to curb glucose absorption, prompt insulin release and shield the pancreatic beta cells that produce it.
White mulberry carries two compounds, rutin and quercetin-3-O-?-D-glucoside, that switch on the AMPK and Akt pathways governing glucose uptake. Red ginseng — steamed and dried Panax ginseng — supplies ginsenosides that improve insulin sensitivity and help regulate oxidative stress. Pomegranate rounds out the list on the strength of its phenols, tannins and triterpenoids; flower extracts lowered blood glucose in animal studies, while peel extracts restored the body's own antioxidant defenses.
What this means at the grocery store
One honest caveat first: nearly all of this evidence comes from cell cultures and lab animals, not people. The authors say that clinical studies are lacking for most of the plants reviewed, and the doses that worked in a lab may exceed anything a tea or capsule delivers. Promising is not the same as proven, and no one should drop a prescription over a mouse study.
That said, three of these four plants are food, and there is no risk in eating well. Fresh pomegranate seeds go into yogurt or a salad; 100 percent juice with no added sugar works, too. White mulberry comes as dried berries, tea or leaf extract. Red ginseng makes a calming tea. Gymnema is mostly sold as a supplement, though it brews into a grassy, herbal tea as well.
The broader point holds regardless of what the trials eventually show: a diet built on fiber, real protein and colorful, polyphenol-dense plants remains the most reliable foundation for blood sugar control anyone has found.
The research nobody is funding
Here is the troubling part. This review received no funding at all. Sixteen plants with credible molecular evidence, converging on the same biological pathways as billion-dollar drugs, and the work of cataloguing them fell to a small team of academics working for free.
There is no patent on a pomegranate. There is no revenue model in telling a diabetic to eat better, and no sales force for a mulberry leaf. The trials that would settle these questions — standardized extracts, real dosing data, human subjects — are exactly the trials no company has an incentive to pay for.
None of which makes these plants a cure. It makes them a question that deserves an answer, and patients deserve to know why they aren't getting one.
Sources for this article include:
Please contact us for more information.